An international consensus process, endorsed by 56 professional and patient organisations, has renamed polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome. The old name described a misnomer: the ovarian appearance reflects numerous arrested antral follicles, not pathological cysts, and the legacy term pushed clinicians towards an ovarian, fertility-centred view of what is a lifelong endocrine-metabolic condition.
The diagnostic criteria do not change — two of three: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and raised anti-Mullerian hormone or multiple follicles on ultrasound in adults. What changes is the clinical frame. The condition affects about 10 to 13 percent of reproductive-age women, is widely underdiagnosed, and is linked to insulin resistance, mood disorder and cardiometabolic risk across life.
In obstetric care it matters at booking. The condition is associated with miscarriage, gestational diabetes, hypertensive disorders, caesarean, preterm birth and growth restriction, with many associations holding after adjustment for age and body mass index. The practical shift is to record it as an obstetric risk modifier and to screen and counsel for metabolic and psychological risk, not just fertility.
- Diagnostic criteria are unchanged: two of three — ovulatory dysfunction, clinical or biochemical hyperandrogenism, raised anti-Mullerian hormone or multiple follicles on ultrasound in adults.
- Affects about 10 to 13 percent of reproductive-age women and is widely underdiagnosed.
- Flag it at the first antenatal visit: it is linked to miscarriage, gestational diabetes, hypertensive disorders, preterm birth and growth restriction.
- Screen and counsel for insulin resistance, mood disorder and long-term cardiometabolic risk, not only fertility.
- The rename came from a consensus endorsed by 56 professional and patient organisations.
Why it matters
The old name framed a whole-body metabolic disorder as an ovarian one, which is a large part of why its cardiometabolic risks go unrecorded.
Don't overread it
The associations with adverse pregnancy outcomes are observational, and the rename does not itself change treatment thresholds.
The statistics, in plain English
The 10 to 13 percent prevalence and the pregnancy-outcome links come from pooled observational data; the adjusted associations describe risk, not proof that the condition causes each outcome.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free